The T309G MDM2 gene polymorphism is a novel risk factor for proliferative vitreoretinopathy

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Pastor Idoate, Salvador ^a,b   Rodríguez Hernández, Irene ^b,c   Rojas, Jimena ^a   Fernández, Itziar ^a   García Gutiérrez, María T ^a   Ruiz Moreno, José M ^d   Rocha Sousa, Amandio ^e   Ramkissoon, Yashin ^f   Harsum, Steven ^f   MacLaren, Robert E ^f,g   Charteris, David ^f   Vanmeurs, Jan C ^h   González Sarmiento, Rogelio ^b,c   Pastor, José C ^a  

^a UNIVERSITY OF VALLADOLID   (Spain)

^b UNIVERSITY OF SALAMANCA   (Spain)

^c UNIVERSITY OF SALAMANCA   (Spain)

^d UNIVERSITY OF CASTILLA LA MANCHA   (Spain)

^e UNIVERSITY OF PORTO   (Portugal)

^f NATIONAL INSTITUTES OF HEALTH   (United States)

^g UNIVERSITY OF OXFORD   (United Kingdom)

^h ROTTERDAM EYE HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN MDM2; PROTEIN P53;

ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; ETHNIC GROUP; EUROPEAN; FEMALE; GENE FREQUENCY; GENE INTERACTION; GENETIC DIFFERENCE; GENETIC RISK; GEOGRAPHIC DISTRIBUTION; HETEROZYGOTE; HUMAN; INTRON; MAJOR CLINICAL STUDY; MALE; MDM2 GENE; MOLECULAR PATHOLOGY; NETHERLANDS; P53 GENE; PORTUGAL; SPAIN; UNITED KINGDOM; VITREORETINOPATHY;

CASE-CONTROL STUDIES; EPISTASIS, GENETIC; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GREAT BRITAIN; HUMANS; INHERITANCE PATTERNS; MALE; NETHERLANDS; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS C-MDM2; RISK FACTORS; TUMOR SUPPRESSOR PROTEIN P53; VITREORETINOPATHY, PROLIFERATIVE;

EID: 84891946417     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0082283     Document Type: Article

References (60)

1. Machemer R, Aaberg TM, Freeman HM, Irvine AR, Lean JS, et al. (1991) An updated classification of retinal detachment with proliferative vitreoretinopathy. Am J Ophthalmol 112:159-165.
2. De La Rua ER, Pastor JC, Fernandez I, Sanabria MR, Garcia-Arumi J, et al. (2008) Non-complicated retinal detachment management: variations in 4 years. Retina 1 project; report 1. Br J Ophthalmol 92:523-525. (Pubitemid 351497982)
3. Miller B, Miller H, Patterson R, Ryan SJ (1986) Retinal wound healing. Cellular activity at the vitreoretinal interface. Arch Ophthalmol 104:281-285. (Pubitemid 16119632)
4. Scott JD (1989) Pathogenesis of PVR with analysis of events leading to recurrent retinal detachment. In: P HKaW, editor. Proliferative Vitreoretinopathy. Kaden, Heidelberg. pp. 150-153.
5. Pastor JC (1998) Proliferative vitreoretinopathy: an overview. Surv Ophthalmol 43:3-18. (Pubitemid 28364465)
6. Wiedemann P (1992) Growth factors in retinal diseases: proliferative vitreoretinopathy, proliferative diabetic retinopathy, and retinal degeneration. Surv Ophthalmol 36:373-384.
7. Zacks DN, Han Y, Zeng Y, Swaroop A (2006) Activation of signaling pathways and stress-response genes in an experimental model of retinal detachment. Invest Ophthalmol Vis Sci 47:1691-1695. (Pubitemid 46804437)
8. El-Ghrably IA, Dua HS, Orr GM, Fischer D, Tighe PJ (2001) Intravitreal invading cells contribute to vitreal cytokine milieu in proliferative vitreoretinopathy. Br J Ophthalmol 85:461-470. (Pubitemid 32275629)
9. Banerjee S, Savant V, Scott RA, Curnow SJ, Wallace GR, et al. (2007) Multiplex bead analysis of vitreous humor of patients with vitreoretinal disorders. Invest Ophthalmol Vis Sci 48:2203-2207. (Pubitemid 351261295)
10. Campochiaro PA, Hackett SF, Vinores SA (1996) Growth factors in the retina and retinal pigmented epithelium. Prog Ret Eye Res 15:547-567. (Pubitemid 26329184)
11. Charteris DG (1998) Growth factors in proliferative vitreoretinopathy. Br J Ophthalmol 82:106. (Pubitemid 28176981)
12. Liou GI, Pakalnis VA, Matragoon S, Samuel S, Behzadian MA, et al. (2002) HGF regulation of RPE proliferation in an IL-1beta/retinal hole-induced rabbit model of PVR. Mol Vis 8:494-501. (Pubitemid 36153643)
13. Hinton DR, He S, Jin ML, Barron E, Ryan SJ (2002) Novel growth factors involved in the pathogenesis of proliferative vitreoretinopathy. Eye (Lond) 16:422-428. (Pubitemid 34845970)
14. Harada C, Mitamura Y, Harada T (2006) The role of cytokines and trophic factors in epiretinal membranes: involvement of signal transduction in glial cells. Prog Retin Eye Res 25:149-164. (Pubitemid 43227842)
15. Mukherjee S, Guidry C (2007) The insulin-like growth factor system modulates retinal pigment epithelial cell tractional force generation. Invest Ophthalmol Vis Sci 48:1892-1899. (Pubitemid 351261379)
16. Pastor JC, De La Rua ER, Martin F (2002) Proliferative vitreoretinopathy: risk factors and pathobiology. Prog Retin Eye Res 21:127-144. (Pubitemid 34242710)
17. Pastor JC, Mendez MC, De La Fuente MA, Coco RM, Garcia-Arumi J, et al. (2006) Intraretinal immunohistochemistry findings in proliferative vitreoretinopathy with retinal shortening. Ophthalmic Res 38:193-200. (Pubitemid 44213979)
18. The Retina Society Terminology Committee. (1983) The classification of retinal detachment with proliferative vitreoretinopathy. Ophthalmology 90:121-125.
19. Michels RG, Wilkinson CP, Rice TA (1990) Retinal Detachment; Mosby, editor.
20. Mietz H, Heimann K (1995) Onset and recurrence of proliferative vitreoretinopathy in various vitreoretinal disease. Br J Ophthalmol 79:874-877.
21. Patel NN, Bunce C, Asaria RH, Charteris DG (2004) Resources involved in managing retinal detachment complicated by proliferative vitreoretinopathy. Retina 24:883-887. (Pubitemid 39657484)
22. Aylward GW (2008) Ophtalmology Chapter 6. In: Mosby, editor. Proliferative Vitreoretinopathy. 3rd ed. pp. 41.
23. Silicone Study Group. (1992) Vitrectomy with silicone oil or sulfur hexafluoride gas in eyes with severe proliferative vitreoretinopathy: results of a randomized clinical trial. Silicone Study Report 1. Arch Ophthalmol 110:770-779.
24. Silicone Study Group (1992) Vitrectomy with silicone oil or perfluoropropane gas in eyes with severe proliferative vitreoretinopathy: results of a randomized clinical trial. Silicone Study Report 2. Arch Ophthalmol 110:780-792.
25. Lewis H, Aaberg TM, Abrams GW (1991) Causes of failure after initial vitreoretinal surgery for severe proliferative vitreoretinopathy. Am J Ophthalmol 111:8-14.
26. Lewis H, Aaberg TM (1991) Causes of failure after repeat vitreoretinal surgery for recurrent proliferative vitreoretinopathy. Am J Ophthalmol 111:15-19.
27. Charteris DG, Aylward GW, Wong D, Groenewald C, Asaria RH, et al. (2004) A randomized controlled trial of combined 5-fluorouracil and low-molecularweight heparin in management of established proliferative vitreoretinopathy. Ophthalmology 111:2240-2245. (Pubitemid 39575594)
28. Turgut B, Uyar F, Ustundag B, Celiker U, Akpolat N, et al. (2012) The impact of tacrolimus on growth factors in experimental proliferative vitreoretinopathy. Retina 32:232-241.
29. Schiff WM, Hwang JC, Ober MD, Olson JL, Dhrami-Gavazi E, et al. (2007) Safety and efficacy assessment of chimeric ribozyme to proliferating cell nuclear antigen to prevent recurrence of proliferative vitreoretinopathy. Arch Ophthalmol 125:1161-1167. (Pubitemid 47403020)
30. Rodriguez De La Rua E, Pastor JC, Aragon J, Mayo-Iscar A, Martinez V, et al. (2005) Interaction between surgical procedure for repairing retinal detachment and clinical risk factors for proliferative vitreoretinopathy. Curr Eye Res 30:147-153. (Pubitemid 40516090)
31. Sanabria Ruiz-Colmenares MR, Pastor Jimeno JC, Garrote Adrados JA, Telleria Orriols JJ, Yugueros Fernandez MI (2006) Cytokine gene polymorphisms in retinal detachment patients with and without proliferative vitreoretinopathy: a preliminary study. Acta Ophthalmol Scand 84:309-313.
32. Rojas J, Fernandez I, Pastor JC, Garcia-Gutierrez MT, Sanabria MR, et al. (2010) A strong genetic association between the tumor necrosis factor locus and proliferative vitreoretinopathy: the retina 4 project. Ophthalmology 117:2417-2423 e2411-2412.
33. Pastor-Idoate S, Rodriguez-Hernandez I, Rojas J, Fernandez I, Garcia-Gutierrez MT, et al. (2013) The p53 codon 72 polymorphism (rs1042522) is associated with proliferative vitreoretinopathy: the Retina 4 Project. Ophthalmology 120:623-628.
34. Rojas J, Fernandez I, Pastor JC, Maclaren RE, Ramkissoon Y, et al. (2013) A genetic case-control study confirms the implication of SMAD7 and TNF locus in the development of proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 54:1665-1678.
35. Moysidis SN, Thanos A, Vavvas DG (2012) Mechanisms of inflammation in proliferative vitreoretinopathy: from bench to bedside. Mediators Inflamm 2012:815937.
36. Rosenbaum DM, Rosenbaum PS, Gupta H, Singh M, Aggarwal A, et al. (1998) The role of the p53 protein in the selective vulnerability of the inner retina to transient ischemia. Invest Ophthalmol Vis Sci 39:2132-2139. (Pubitemid 28455083)
37. Cook B, Lewis GP, Fisher SK, Adler R (1995) Apoptotic photoreceptor degeneration in experimental retinal detachment. Invest Ophthalmol Vis Sci 36:990-996.
38. Arroyo JG, Yang L, Bula D, Chen DF (2005) Photoreceptor apoptosis in human retinal detachment. Am J Ophthalmol 139:605-610.
39. Ricker LJ, Altara R, Goezinne F, Hendrikse F, Kijlstra A, et al. (2011) Soluble apoptotic factors and adhesion molecules in rhegmatogenous retinal detachment. Invest Ophthalmol Vis Sci 52:4256-4262.
40. Lo AC, Woo TT, Wong RL, Wong D (2011) Apoptosis and other cell death mechanisms after retinal detachment: implications for photoreceptor rescue. Ophthalmologica 226 Suppl 1:10-17.
41. Moll UM, Petrenko O (2003) The MDM2-p53 interaction. Mol Cancer Res 1:1001-1008. (Pubitemid 38044975)
42. Iwakuma T, Lozano G (2003) MDM2, an introduction. Mol Cancer Res 1:993-1000. (Pubitemid 38044974)
43. Lei H, Rheaume MA, Cui J, Mukai S, Maberley D, et al. (2012) A novel function of p53: a gatekeeper of retinal detachment. Am J Pathol 181:866-874.
44. Bond GL, Hu W, Levine A (2005) A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect. Cancer Res 65:5481-5484. (Pubitemid 40911143)
45. Bougeard G, Baert-Desurmont S, Tournier I, Vasseur S, Martin C, et al. (2006) Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome. J Med Genet 43:531-533. (Pubitemid 43927330)
46. Di Vuolo V, Buonaguro L, Izzo F, Losito S, Botti G, et al. (2011) TP53 and MDM2 gene polymorphisms and risk of hepatocellular carcinoma among Italian patients. Infect Agent Cancer 6:13.
47. Alhopuro P, Ylisaukko-Oja SK, Koskinen WJ, Bono P, Arola J, et al. (2005) The MDM2 promoter polymorphism SNP309T-. G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck. J Med Genet 42:694-698. (Pubitemid 41306059)
48. Akaike H (1974) A new look at the statistical model identification. IEEE Trans Automat Contr 19:716-723.
49. R Development Core Team. (2010) R: A language and environment for statistical computing. R Foundation for Statistical Computing. Vienna, Austria. pp. Available at: http://www.R-project.org/Accessed April 2, 2012.
50. Elmore S (2007) Apoptosis: a review of programmed cell death. Toxicol Pathol 35:495-516. (Pubitemid 46911891)
51. Saika S, Kono-Saika S, Tanaka T, Yamanaka O, Ohnishi Y, et al. (2004) Smad3 is required for dedifferentiation of retinal pigment epithelium following retinal detachment in mice. Lab Invest 84:1245-1258. (Pubitemid 40063691)
52. Saika S, Yamanaka O, Nishikawa-Ishida I, Kitano A, Flanders KC, et al. (2007) Effect of Smad7 gene overexpression on transforming growth factor betainduced retinal pigment fibrosis in a proliferative vitreoretinopathy mouse model. Arch Ophthalmol 125:647-654. (Pubitemid 46762726)
53. Yu J, Peng R, Chen H, Cui C, Ba J (2012) Elucidation of the pathogenic mechanism of rhegmatogenous retinal detachment with proliferative vitreoretinopathy by proteomic analysis. Invest Ophthalmol Vis Sci 53:8146-8153.
54. Bhattacharya S, Ray RM, Chaum E, Johnson DA, Johnson LR (2011) Inhibition of Mdm2 sensitizes human retinal pigment epithelial cells to apoptosis. Invest Ophthalmol Vis Sci 52:3368-3380.
55. Zhang C, Rosenbaum DM, Shaikh AR, Li Q, Rosenbaum PS, et al. (2002) Ischemic preconditioning attenuates apoptotic cell death in the rat retina. Invest Ophthalmol Vis Sci 43:3059-3066. (Pubitemid 34977060)
56. Yang P, McKay BS, Allen JB, Jaffe GJ (2004) Effect of NF-kappa B inhibition on TNF-alpha-induced apoptosis in human RPE cells. Invest Ophthalmol Vis Sci 45:2438-2446. (Pubitemid 38902620)
57. Assmann G, Wagner AD, Monika M, Pfoehler C, Pfreundschuh M, et al. (2010) Single-nucleotide polymorphisms p53 G72C and Mdm2 T309G in patients with psoriasis, psoriatic arthritis, and SAPHO syndrome. Rheumatol Int 30:1273-1276.
58. Brennan RC, Federico S, Bradley C, Zhang J, Flores-Otero J, et al. (2011) Targeting the p53 pathway in retinoblastoma with subconjunctival Nutlin-3a. Cancer Res 71:4205-4213.
59. Dempfle A, Scherag A, Hein R, Beckmann L, Chang-Claude J, et al. (2008) Gene-environment interactions for complex traits: definitions, methodological requirements and challenges. Eur J Hum Genet 16:1164-1172.
60. Crawford DC, Nickerson DA (2005) Definition and clinical importance of haplotypes. Annu Rev Med 56:303-320. (Pubitemid 40299785)